Overview

Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels, respectively. The intravenous infusion will be initiated by a pre-defined bolus dose infusion.
Phase:
Phase 2
Details
Lead Sponsor:
Dilafor AB
Treatments:
Oxytocin